Autogen becomes AGT Biosciences
20 March, 2003 by Melissa TrudingerAs the final step in a process of transformation that has taken almost a year, Victorian gene discovery company Autogen (ASX: AGT) has rebadged itself as AGT Biosciences.
Promics feeling optimistic after trials
20 March, 2003 by Pete YoungBrisbane biotech Promics is feeling optimistic after successfully concluding human toxicity and safety trials on its anti-inflammatory drug PMX 53.
Brain Resource Company signs with IBM
19 March, 2003 by Jeremy TorrSydney-based Brain Resource Company (BRC) has signed a business partner deal with IBM to tie up its innovative Integ Neuro series of cognitive performance tests to IBM's integrated Countertop kiosk input devices.
Autogen strengthens Merck-Sante partnership
19 March, 2003 by Melissa TrudingerAutogen has signed two more commercialisation and licensing deals with partner Merck-Sante for genes related to diabetes and obesity, bringing to four the number of gene targets selected for fast-tracked development by Merck.
NSW farmers to discuss GM crops
14 March, 2003 by Jeremy Torr"Most farmers' knowledge level when it comes to GM crops is just too low for them to make informed decisions." So says Angus Macneil, Chair of the Association Grains Committee, NSW Farmers' Association.
Brisbane biotechs get cosy in manufacturing contract
12 March, 2003 by Pete YoungA drug manufacturing contract signed between two Brisbane biotech companies shows how Queensland's maturing biotech sector is creating opportunities for cross-pollination between its different layers.
GTG signs $5m deal with Swedish firm
11 March, 2003 by Jeremy TorrMelbourne-based Genetic Technologies (GTG) has inked its biggest deal yet, with Swedish DNA company Pyrosequencing.
USQ whoops it up for cough vaccine
10 March, 2003 by Pete YoungAustralian developers of a genetically-engineered vaccine against whooping cough are taking some of the wraps off their work in a bid to attract funding for human clinical trials.
States, Feds divided on GM crops
07 March, 2003 by Pete YoungGovernment opposition to genetically modified food crops is hardening at the State level, even as the potential approval for such crops draws nearer at the Federal level.
Progen half year results show revenue continues to rise
07 March, 2003 by Pete YoungHalf year results for drug developer Progen Industries reveal revenues from its contract drug manufacturing and life sciences sales and distribution arms continue to rise, helping offset development costs of its anti-cancer drug candidates.
Pulmosonix gets grant for device development
06 March, 2003 by Melissa TrudingerResearchers at Melbourne-based devices company Pulmosonix have received a $AUD165,000 development grant from the NHMRC to work on a new device for simple and non-invasive assessment of the condition of deeper tissues and organs.
Meditech gears up for Phase II anti-cancer trials
05 March, 2003 by Melissa TrudingerMeditech Research has been granted ethics committee approval to begin a Phase II clinical trial testing two anti-cancer drugs, HyFIVE and HyCAMP, on colorectal cancer patients, the company said yesterday.
Metabolic obesity drug proven safe in trial
03 March, 2003 by Melissa TrudingerMelbourne biotech company Metabolic Pharmaceuticals announced the results of the Phase IIa clinical trial for its anti-obesity drug AOD9604 today, confirming the safety of the drug.
Agenix readies for phase I trials, pre-tax profits up
28 February, 2003 by Pete YoungBrisbane biotech Agenix saw its first half revenues decline slightly while posting a 32 per cent rise in before-tax profits on a like-to-like comparison with the same period last year.
Bioactives easier to source than funds, companies find
28 February, 2003 by Pete YoungIt is easier to ferret out promising bioactive compounds in Australia's plant kingdom than it is to extract fresh funds from the investor community, young bioprospecting companies are discovering.
